Innovative RNA Drugs Offer Hope for Patients with High Cholesterol

▴ Innovative RNA Drugs Offer Hope for Patients with High Cholesterol
If successful, these drugs could become a mainstay in the treatment of hyperlipidemia and related conditions, reducing the incidence of heart disease and improving the quality of life for many patients.

Recent studies published in the New England Journal of Medicine have revealed promising results for new gene-based drugs that could help lower cholesterol levels in patients with naturally high levels of lipids in their blood. These innovative treatments, named plozasiran and zodasiran, have shown significant efficacy and safety in early-stage clinical trials, offering hope for patients struggling with high cholesterol.

Understanding Gene-Based Drugs: Gene-based drugs, like plozasiran and zodasiran, utilize RNA (ribonucleic acid) to achieve their therapeutic effects. RNA is a crucial molecule present in all living organisms, formed from DNA (deoxyribonucleic acid). It plays a pivotal role in converting genetic information from DNA into proteins that regulate various bodily functions. The RNA material in these drugs binds with the body's natural RNA, preventing the production of proteins that contribute to high cholesterol levels.

Mechanism of Action: Plozasiran works by limiting the formation of a protein called apolipoprotein C3, which plays a role in regulating triglyceride levels. Zodasiran, on the other hand, reduces the production of angiopoietin-like 3 (ANGPTL3) protein. Both proteins are associated with higher levels of "bad" cholesterol (LDL) and triglycerides, which can increase the risk of heart disease and other health issues.

Plozasiran: The plozasiran trial involved 353 participants divided into different cohorts. The participants received varying doses of the drug—10 milligrams (mg), 25 mg, or 50 mg—administered either quarterly (every 12 weeks) or biannually (every 24 weeks).

- 10 mg Quarterly Dose: Triglyceride levels reduced by nearly 50% at week 24.
- 25 mg Quarterly Dose: Triglyceride levels decreased by 56% at week 24.
- 50 mg Quarterly Dose: Triglyceride levels fell by 62.4% at week 24.
- 50 mg Biannual Dose: Triglyceride levels dropped by 44.2% at week 24.

Zodasiran: The zodasiran trial included 204 participants who were randomly assigned to receive either the drug (in doses of 50 mg, 100 mg, or 200 mg) or a placebo. The treatment was administered subcutaneously on day 1 and week 12, with follow-up extending to week 36.

- 50 mg Dose: Reduced non-HDL cholesterol by 29 percentage points and LDL cholesterol by 16 percentage points.
- 100 mg Dose: Lowered non-HDL cholesterol by 29 percentage points and LDL cholesterol by 14 percentage points.
- 200 mg Dose: Decreased non-HDL cholesterol by 36 percentage points and LDL cholesterol by 20 percentage points.

Safety and Efficacy: Both drugs demonstrated a favorable safety profile, with no significant adverse events related to liver function reported. Zodasiran, in particular, was associated with reduced liver fat at week 24, indicating additional health benefits. Arrowhead Pharmaceuticals, the developer of these RNA-based medicines, continues to monitor and report the safety and efficacy of these treatments.

The Potential Impact: High levels of "bad" cholesterol and triglycerides are major risk factors for cardiovascular diseases. Traditional treatments like statins have been effective for many, but there are patients with conditions like mixed hyperlipidemia who need more potent solutions. The introduction of gene-based drugs like plozasiran and zodasiran could revolutionize the management of high cholesterol, providing an alternative for those who do not respond well to existing medications.

Future Directions: As the clinical trials progress, further research will determine the long-term efficacy and safety of plozasiran and zodasiran. If successful, these drugs could become a mainstay in the treatment of hyperlipidemia and related conditions, reducing the incidence of heart disease and improving the quality of life for many patients.

The development of gene-based drugs represents a significant advancement in medical science. By targeting the genetic causes of high cholesterol, these treatments offer a new hope for patients with lipid disorders. The encouraging results from the early-stage trials of plozasiran and zodasiran suggest that these drugs could play a crucial role in future cholesterol management strategies.

Arrowhead Pharmaceuticals continues to lead the way in developing RNA-based medicines, demonstrating the potential of gene silencing technologies in treating intractable diseases. As research advances, we can look forward to more innovative treatments that address the root causes of various health conditions, paving the way for a healthier future.

Tags : #

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

07 Sep

JNCASR researchers develop diagnostic therapy for Lung Cancer

Now a safe and cheap way for determining lungs cancer

View
29 Aug

Citriodiol in insect repellent may protect against COVID-19: UK study

Citriodiol had anti-viral properties if mixed with the virus in the liquid phase and on a test surface

View
05 Aug

INST develops new kit to detect fluoride in drinking water

Equipment-free, a simple paper-strip based naked-eye fluoride ion detection and quantification kit in drinking water to evade Fluorosis-based disorders

View
29 Jul

SNBNCBS develops a device for screening of bilirubin level in new born

The operation of the device is based on non-contact and non-invasive spectrometry-based techniques for measurement of neonatal bilirubin level

View
17 Jul

ARCI & Vehant Technologies co-develop UV System for baggage

ARCI & Vehant Technologies co-develop UV System for baggage Scan Disinfection to fight COVID 19

View
15 Jul

Atal Innovation Mission to support Startups with COVID-19 Solutions

9 startups were chosen in the first round for funding

View
26 May

Molecular shock absorbers buffer axonal tension of nerve cells : RRI

Department of Science &Technology along with IISER Pune have proved Spectrin act as ‘shock absorbers’

View
14 May

DST initiatives to protect Divyangjan and Elderly

PSG College of Technology

View
13 Apr

IUSSTF boosts Indo-US virtual networks to address COVID 19 challenges

Collaboration across nations and organizations can leverage and share expertise across S&T communities and facilitate the development of a diverse, globally-engaged science, engineering, and technology-abled workforce, which can proactively work towards solutions for the Pandemic

View
07 Apr

Chandigarh University Uses 3D Printing Technology to Design Splitters That can Bridge Ventilators Shortfall in India

Chandigarh University had constituted a Core Research Group on the call made by Department of Science and Technology (DST) which had invited proposals from companies

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025